Alan Barge

2.0k total citations
21 papers, 1.5k citations indexed

About

Alan Barge is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Alan Barge has authored 21 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 8 papers in Hematology and 7 papers in Molecular Biology. Recurrent topics in Alan Barge's work include Acute Myeloid Leukemia Research (6 papers), Cancer Treatment and Pharmacology (6 papers) and Angiogenesis and VEGF in Cancer (5 papers). Alan Barge is often cited by papers focused on Acute Myeloid Leukemia Research (6 papers), Cancer Treatment and Pharmacology (6 papers) and Angiogenesis and VEGF in Cancer (5 papers). Alan Barge collaborates with scholars based in United Kingdom, Germany and United States. Alan Barge's co-authors include Catherine Wheeler, M. Boogaerts, A. Zander, H Demuynck, A. H. Goldstone, Keith M. Borkett, Hartmut Link, David C. Linch, Augustin Ferrant and Peter Dreger and has published in prestigious journals such as The Lancet, Blood and Oncogene.

In The Last Decade

Alan Barge

20 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alan Barge United Kingdom	14	819	664	411	250	183	21	1.5k
John D. Bonnet United States	22	1.0k 1.2×	745 1.1×	620 1.5×	264 1.1×	149 0.8×	41	1.7k
Antoine Yver United States	17	1.3k 1.5×	386 0.6×	344 0.8×	420 1.7×	112 0.6×	36	1.8k
José Luís Passos‐Coelho Portugal	21	913 1.1×	279 0.4×	273 0.7×	288 1.2×	93 0.5×	46	1.4k
William J. Edenfield United States	19	783 1.0×	661 1.0×	674 1.6×	741 3.0×	394 2.2×	101	2.1k
Sharianne G. Louie United States	11	581 0.7×	859 1.3×	1.0k 2.5×	514 2.1×	403 2.2×	12	2.0k
Elena De Mattia Italy	25	963 1.2×	239 0.4×	725 1.8×	324 1.3×	95 0.5×	92	2.0k
Stephen Shibata United States	28	1.2k 1.4×	275 0.4×	433 1.1×	601 2.4×	130 0.7×	84	2.2k
Edoardo Ascari Italy	25	566 0.7×	623 0.9×	873 2.1×	337 1.3×	557 3.0×	96	2.2k
Alberto Bessudo United States	18	609 0.7×	388 0.6×	517 1.3×	105 0.4×	258 1.4×	70	1.2k
J J Costanzi United States	20	641 0.8×	187 0.3×	295 0.7×	283 1.1×	158 0.9×	36	1.2k

Countries citing papers authored by Alan Barge

Since Specialization

Citations

This map shows the geographic impact of Alan Barge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Barge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Barge more than expected).

Fields of papers citing papers by Alan Barge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan Barge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Barge. The network helps show where Alan Barge may publish in the future.

Co-authorship network of co-authors of Alan Barge

This figure shows the co-authorship network connecting the top 25 collaborators of Alan Barge. A scholar is included among the top collaborators of Alan Barge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan Barge. Alan Barge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Barge, Alan, et al.. (2024). Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms. Oncogene. 44(4). 193–207. 27 indexed citations

2.

Roohullah, Aflah, Adam Cooper, Anna J. Lomax, et al.. (2018). A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers. Investigational New Drugs. 36(5). 886–894. 23 indexed citations

3.

Kim, Jihyeung, Seock‐Ah Im, Kyoung Bun Lee, et al.. (2014). Phase Iia Study to Evaluate the Biological Activity of Aslan001 in Her-1/2 Co-Expressing or Her-2 Amplified Advanced Gastric Cancer. Annals of Oncology. 25. iv226–iv226. 2 indexed citations

4.

LoRusso, Patricia, Shirish M. Gadgeel, Antoinette Wozniak, et al.. (2008). Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Investigational New Drugs. 26(2). 159–167. 54 indexed citations

5.

Conrad, Claudius, Ivan Ischenko, Gudrun Köhl, et al.. (2007). Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model. Anti-Cancer Drugs. 18(5). 569–579. 25 indexed citations

6.

Stone, Andrew, Catherine Wheeler, & Alan Barge. (2006). Improving the design of phase II trials of cytostatic anticancer agents. Contemporary Clinical Trials. 28(2). 138–145. 31 indexed citations

7.

Stone, Andrew, Catherine Wheeler, Kevin Carroll, & Alan Barge. (2006). Optimizing randomized phase II trials assessing tumor progression. Contemporary Clinical Trials. 28(2). 146–152. 19 indexed citations

8.

Holden, Scott N., Sabine Eckhardt, R. Basser, et al.. (2005). Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Annals of Oncology. 16(8). 1391–1397. 247 indexed citations

9.

Baselga, José, Federico Rojo, Andy Ryan, et al.. (2005). Pharmacodynamic assessment of ZD6474 (ZACTIMA (TM)) in the skin of patients with previously treated metastatic breast cancer.. Clinical Cancer Research. 11. 1 indexed citations

10.

Miller, Kathy D., José Trigo, Catherine Wheeler, et al.. (2005). A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Previously Treated Metastatic Breast Cancer. Clinical Cancer Research. 11(9). 3369–3376. 155 indexed citations

11.

Kleespies, Axel, Gudrun Köhl, Michael Friedrich, et al.. (2005). Vascular Targeting in Pancreatic Cancer: The Novel Tubulin-Binding Agent ZD6126 Reveals Antitumor Activity in Primary and Metastatic Tumor Models. Neoplasia. 7(10). 957–966. 15 indexed citations

12.

Yezhelyev, Maksim, Gudrun E. Koehl, Markus Guba, et al.. (2004). Inhibition of Src Tyrosine Kinase as Treatment for Human Pancreatic Cancer Growing Orthotopically in Nude Mice. Clinical Cancer Research. 10(23). 8028–8036. 108 indexed citations

13.

Akaza, Hideyuki, Koji Kawai, Kazuhiro Aiba, et al.. (2001). [Comparison of management of advanced cancer in various organs].. PubMed. 28(12). 1845–55.

14.

Archimbaud, E, Oliver G. Ottmann, John A. Liu Yin, et al.. (1999). A Randomized, Double-Blind, Placebo-Controlled Study With Pegylated Recombinant Human Megakaryocyte Growth and Development Factor (PEG-rHuMGDF) as an Adjunct to Chemotherapy for Adults With De Novo Acute Myeloid Leukemia. Blood. 94(11). 3694–3701. 83 indexed citations

15.

Geißler, Klaus, Eva Kabrna, Ilse Schwarzinger, et al.. (1998). Recombinant human megakaryocyte growth and development factor increases levels of circulating haemopoietic progenitor cells post chemotherapy in patients with acute myeloid leukaemia. British Journal of Haematology. 102(2). 535–543. 13 indexed citations

16.

Heil, Gerhard, Dieter Hoelzer, Miguel Á. Sanz, et al.. (1997). A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Filgrastim in Remission Induction and Consolidation Therapy for Adults With De Novo Acute Myeloid Leukemia. Blood. 90(12). 4710–4718. 231 indexed citations

17.

Heil, Gerhard, Dieter Hoelzer, Miguel Á. Sanz, et al.. (1997). A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Filgrastim in Remission Induction and Consolidation Therapy for Adults With De Novo Acute Myeloid Leukemia. Blood. 90(12). 4710–4718. 11 indexed citations

18.

Schmitz, Norbert, Peter Dreger, David C. Linch, et al.. (1996). Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. The Lancet. 347(8998). 353–357. 462 indexed citations

19.

Heil, Gerhard, Miguel Á. Sanz, Klaus Lechner, et al.. (1995). Results of a randomised, double-blind placebo controlled phase III study of filgrastim in remission induction and early consolidation therapy for adults with de-novo acute myeloid leukemia. Ghent University Academic Bibliography (Ghent University). 12 indexed citations

20.

Dausset, J, Franck Rapaport, Alan Barge, et al.. (1967). [The ABO system and transplantation. Effect of pre-immunization with soluble A substance].. PubMed. 75(29). 1503–8. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact